Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol

BACKGROUND: Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease. Its serious clinical consequences include renal osteodystrophy, calcific uremic arteriolopathy, and vascular calcifications that increase morbidity and mortality. Reduced synthesis of active vitami...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Ditte, Brandi, Lisbet, Rasmussen, Knud
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760547/
https://www.ncbi.nlm.nih.gov/pubmed/19778452
http://dx.doi.org/10.1186/1471-2369-10-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760547/
https://www.ncbi.nlm.nih.gov/pubmed/19778452
http://dx.doi.org/10.1186/1471-2369-10-28

Ejemplares similares